home   |   contact us   |   sitemap     

 
   about Formula Pharmaceuticals  technology  pipeline NewsCareers  
   
   
             
   
Top News

 


Media Contact  

 

 

 

June 4, 2012

Formula Pharmaceuticals Appoints Morton Collins to Board of Directors

Berwyn, PA – June 4, 2012 – Formula Pharmaceuticals Inc., an oncology-focused biopharmaceutical company developing novel therapeutics that target both cancer stem cells (CSCs) and various minimal residual disease settings, announced today the appointment of Morton Collins to its Board of Directors.

“Mr. Collins brings decades of experience in corporate financing and leadership within life science companies,” said Maurits W. Geerlings, Chief Executive Officer of Formula Pharmaceuticals. “We are honored to welcome Mr. Collins to our Board of Directors, at a time when our company is transitioning into a multinational business.”

Earlier in his career, Mr. Collins was the Founder and Chief Executive Officer of Data Science Ventures, Inc. (DSV I). He was a Founder of DSV Associates (DSV II); DSV Partners III (DSV III); DSV Partners IV (DSV IV) and has been the Managing Partner of each entity. These organizations provide venture capital and management assistance to early-stage high-technology companies. In 1997, Mr. Collins became a Special Limited Partner of Cardinal Partners, the successor to the DSV series of partnerships. In 2003, Mr. Collins became a General Partner of Battelle Ventures which he founded. Mr. Collins has served as a Director at Alkermes, Apollon Inc. and The Liposome Company, three successful life science companies.

“By preventing the recurrence of cancer, Formula’s vaccine has the potential to significantly impact survival outcome in a variety of tumor indications. I look forward to working with the Board to fully leverage Formula’s important mission to develop innovative, life-saving cancer therapies for patients,” said Mr. Collins.

In addition to his leadership in numerous life science and technology ventures, Mr. Collins has served on the New Jersey Governor’s Commission on Science and Technology and the New Jersey Governor’s Superconductivity Roundtable. During the Reagan Administration, he chaired the President’s Task Force on Innovation and Entrepreneurship and served as a technology policy advisor to President George H.W. Bush. Mr. Collins earned his B.S. from the University of Delaware and his Masters and Doctorate Degrees from Princeton University. He remains an active alumnus at both institutions.

About Formula Pharmaceuticals

Formula Pharmaceuticals, Inc. is a privately-held, oncology drug development company advancing novel medicines to address areas of unmet therapeutic need in cancer. Formula’s lead product candidate, FPI-01, is a first-in-class immunotherapeutic in clinical development for the maintenance of first-remission in acute myeloid leukemia (AML) and other cancers. Building upon deep industry expertise in identifying, licensing and developing novel medical approaches, Formula's focus is on accelerating future life-saving cancer therapies.

Founded in late 2009 by Dr. Geerlings and Dr. Giorgio Mosconi, Formula has assembled a world-class scientific, clinical development and business team well positioned to maximize the clinical and commercial value of promising drug candidates through excellence in drug development and strategic partnering.
For more information, visit www.formulapharma.com.

Media Contact:
Mike Beyer
Sam Brown Inc.
(312) 961-2502
beyer@sambrown.com